Medicinal Chemistry Journal of Medicinal Chemistry (ACS)

First non-peptide neurolysin activators cut infarct size in a mouse stroke model

  • Neurolysin, a peptidase induced after ischemic stroke, is an emerging neuroprotective target; earlier activators were peptidomimetics.
  • A pyridine-piperazine scaffold gave the first non-peptide activators, with nanomolar potency and better stability and blood-brain barrier penetration than the peptidomimetics.
  • Lead 7g reduced infarct volume and brain water content in the MCAO mouse model, a first for a small-molecule activator.
Points Based on the abstract

Activating an enzyme is a harder claim than inhibiting one: a fluorogenic-substrate readout can mislead if the compounds act in a substrate-dependent way. Before crediting the infarct benefit to neurolysin, I'd want a counter-screen against thimet oligopeptidase, its close homolog, and loss of efficacy in knockout animals. Still, a brain-penetrant non-peptide scaffold is a big step up from peptidomimetics.